The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been filed on behalf of investors who purchased the common stock of Outset Medical, Inc. (“Outset” or the “Company”) (Nasdaq: OM) from September 15, 2020 through June 13, 2022, inclusive (the “Class Period”).

If you purchased Outset common stock during the Class Period, you may move the Court for appointment as lead plaintiff by no later than September 6, 2022. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in the actions will not be affected by your decision of whether to seek appointment as lead plaintiff. You may retain Lieff Cabraser, or other attorneys, as your counsel in the action.

Outset investors who wish to learn more about the litigation and how to seek appointment as lead plaintiff should click here, text or email investorinfo@lchb.com, or call Sharon M. Lee of Lieff Cabraser at 1-800-541-7358.

Background on the Outset Securities Class Litigation

Outset, headquartered in San Jose, California, is a medical technology company whose chief product, the Tablo Hemodialysis System (“Tablo”), is used for the treatment of acute and chronic kidney failure.

The action alleges that, throughout the Class Period, Outset misled investors and/or failed to disclose that: (1) the Company had “continuously made improvements and updates to Tablo over time since its original clearance,” which required further studies and potentially new applications to the U.S. Food and Drug Administration (“FDA”); (2) in the absence of such studies and FDA approval, the Company could not conduct a human factors study on the Tablo pursuant to FDA protocols; and (3) Outset’s inability to conduct the human factors study exposed the Company to the risk of FDA actions, including a shipping hold and marketing suspension, rendering Outset incapable of selling Tablo for home use.

On May 4, 2022, after markets closed, Outset announced disappointing financial results for the first quarter of 2022, which analysts attributed in part to Tablo’s untested performance in the home setting. On this news, the price of Outset common stock fell $16.88, or 2.26% over the next three trading days, from a closing price of $39.94 per share on Wednesday, May 4, 2022, to close at $23.06 per share on Monday, May 9, 2022, on elevated trading volume.

On June 13, 2022, after markets closed, Outset announced that the FDA compelled the Company to suspend all shipments of Tablo for home use until Outset obtained the requisite regulatory clearance. On this news, the price of Outset stock fell $6.95, or 34.05%, from a closing price of $20.41 per share on June 13, 2022, to close at $13.46 per share on June 14, 2022, on extremely heavy trading volume.

About Lieff Cabraser

Lieff Cabraser Heimann & Bernstein, LLP, with offices in San Francisco, New York, Nashville, and Munich, is an internationally-recognized law firm committed to advancing the rights of investors and promoting corporate responsibility. The National Law Journal has recognized Lieff Cabraser as one of the nation’s top plaintiffs’ law firms for fourteen years. Law360 has selected Lieff Cabraser as one of the Top 50 law firms nationwide for litigation, highlighting our firm’s “laser focus” and noting that our firm routinely finds itself “facing off against some of the largest and strongest defense law firms in the world.” Benchmark Litigation has named Lieff Cabraser one of the “Top 10 Plaintiffs’ Firms in America.”

For more information about Lieff Cabraser and the firm’s representation of investors, please visit https://www.lieffcabraser.com/.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220714005240/en/

#OM INVESTORS: September 6, 2022 Deadline in #Securities #ClassAction – Contact Lieff Cabraser #StockNews #OutsetMedical $OM